financetom
Business
financetom
/
Business
/
MicroStrategy leads crypto sector short losses with $2 billion hit since March
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MicroStrategy leads crypto sector short losses with $2 billion hit since March
Apr 10, 2024 6:40 AM

(Reuters) - Short sellers betting against MicroStrategy ( MSTR ) have lost $1.92 billion since March, according to data from S3 Partners, highlighting the hit from a rally that has helped the stock outperform bitcoin.

The approval of several spot bitcoin exchange-traded funds (ETFs) by the Securities and Exchange Commission (SEC) in January has brought the once-nascent asset class closer to the mainstream.

Traders betting against crypto exchange Coinbase and bitcoin miner CleanSpark ( CLSK ) also lost $593.50 million and $106.40 million, respectively, the data showed.

MicroStrategy ( MSTR ) held nearly 190,000 bitcoin on its balance sheet as of the end of 2023 and has indicated it would continue increasing its exposure. It sold convertible debt twice within a week last month to raise money to buy more bitcoin.

"The premium (for MicroStrategy ( MSTR )) is supported by a desire for investors to have exposure to bitcoin who may be unable to invest directly in bitcoin or in ETFs," analysts at BTIG said in a note earlier in April.

The company's ability to raise capital to purchase additional bitcoin is also a positive for shareholders, the brokerage added.

But despite the recent optimism, the crypto industry continues to be heavily shorted. Short interest in nine of the most-watched companies in the crypto space stood at 16.73% of the total number of their outstanding shares, more than three times the average in the United States.

The SEC also remains uncomfortable with crypto and its approval of the spot bitcoin ETFs might not signal willingness to embrace other similar products, like spot ethereum ETFs, Reuters has reported.

The spot bitcoin ETF decision was not "indicative of a change in philosophy at the Commission," said Alan Konevsky, chief legal and corporate affairs officer at online investment platform tZERO.

"I don't think it's a harbinger of more good things to come," he said.

Short sellers sell borrowed shares and hope to buy them back at a lower price later, pocketing the difference.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Canadian Western Bank Q2 Profit, Revenue Rise, but Miss Estimates; Dividend Raised
Canadian Western Bank Q2 Profit, Revenue Rise, but Miss Estimates; Dividend Raised
May 31, 2024
07:57 AM EDT, 05/31/2024 (MT Newswires) -- Canadian Western Bank ( CWESF ) on Friday reported higher profit and revenue for the fiscal second quarter, but the results missed estimates. The bank reported fiscal second-quarter adjusted common shareholders' net income of $78.2 million, or $0.81 per share, up 9% from $71.7 million, or $0.74 per share, a year earlier. Analysts...
Yum China Says it Opened Nine Little Sheep Restaurants in China in May
Yum China Says it Opened Nine Little Sheep Restaurants in China in May
May 31, 2024
07:57 AM EDT, 05/31/2024 (MT Newswires) -- Yum China Holdings ( YUMC ) said Friday its Chinese business unit opened nine Little Sheep restaurants across China in May. Internationally, Yum China ( YUMC ) said a new Little Sheep restaurant opened in the Meadowlands shopping complex in East Rutherford, New Jersey in March. Yum China ( YUMC ) operates the...
Deutsche Bank sees slightly lower fixed income revenue in Q2
Deutsche Bank sees slightly lower fixed income revenue in Q2
May 31, 2024
BERLIN (Reuters) - Deutsche Bank expects a slight decline in its fixed-income business this quarter, but still sees overall revenue of 30 billion euros ($32.56 billion) in 2024, the chief financial officer of Germany's largest bank said. Looking at fixed income and currencies, we would expect that to come in slightly lower in the second quarter versus the prior year's...
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review
May 31, 2024
May 31 (Reuters) - Sanofi and partner Regeneron Pharmaceuticals ( REGN ) have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even as the U.S. Food and Drug Administration (FDA) extended its review. French drugmaker Sanofi and its U.S. partner have been counting on expanding the use of the drug as an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved